P2X Purinoceptor 7 (P2Z Receptor or P2RX7)-Pipeline Review, H2 2017

P2X Purinoceptor 7 (P2Z Receptor or P2RX7)-Pipeline Review, H2 2017


  • Products Id :- GMDHC0954TDB
  • |
  • Pages: 39
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

P2X Purinoceptor 7 (P2Z Receptor or P2RX7)-Pipeline Review, H2 2017

Summary

According to the recently published report 'P2X Purinoceptor 7-Pipeline Review, H2 2017'; P2X Purinoceptor 7 (P2Z Receptor or P2RX7) pipeline Target constitutes close to 9 molecules. Out of which approximately 9 molecules are developed by Companies.

P2X Purinoceptor 7 (P2Z Receptor or P2RX7)-P2X purinoceptor 7 is a protein encoded by the P2RX7 gene. It acts as receptor for ATP that acts as a ligand-gated ion channel. It is responsible for ATP-dependent lysis of macrophages through the formation of membrane pores permeable to large molecules.

The report 'P2X Purinoceptor 7-Pipeline Review, H2 2017' outlays comprehensive information on the P2X Purinoceptor 7 (P2Z Receptor or P2RX7) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in P2X Purinoceptor 7 (P2Z Receptor or P2RX7) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 5 and 1 respectively. Report covers products from therapy areas Central Nervous System, Immunology, Oncology, Gastrointestinal, Genetic Disorders, Metabolic Disorders and Musculoskeletal Disorders which include indications Neuropathic Pain, Inflammation, Multiple Sclerosis, Alzheimer Disease, Autoimmune Disorders, Basal Cell Carcinoma (Basal Cell Epithelioma), Bipolar Disorder (Manic Depression), Charcot-Marie-Tooth Disease Type I A, Depression, Inflammatory Bowel Disease, Major Depressive Disorder, Mania, Muscular Dystrophy, Neurodegenerative Diseases, Osteoarthritis Pain, Psoriasis, Rheumatoid Arthritis, Solid Tumor, Systemic Lupus Erythematosus, Transplant Rejection, Type 1 Diabetes (Juvenile Diabetes) and Visceral Pain.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for P2X Purinoceptor 7 (P2Z Receptor or P2RX7)

The report reviews P2X Purinoceptor 7 (P2Z Receptor or P2RX7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in P2X Purinoceptor 7 (P2Z Receptor or P2RX7) targeted therapeutics and enlists all their major and minor projects

The report assesses P2X Purinoceptor 7 (P2Z Receptor or P2RX7) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to P2X Purinoceptor 7 (P2Z Receptor or P2RX7) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for P2X Purinoceptor 7 (P2Z Receptor or P2RX7)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding P2X Purinoceptor 7 (P2Z Receptor or P2RX7) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

P2X Purinoceptor 7 (P2Z Receptor or P2RX7)-Overview

P2X Purinoceptor 7 (P2Z Receptor or P2RX7)-Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

P2X Purinoceptor 7 (P2Z Receptor or P2RX7)-Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

P2X Purinoceptor 7 (P2Z Receptor or P2RX7)-Companies Involved in Therapeutics Development

Affectis Pharmaceuticals AG

Axxam SpA

Biosceptre International Ltd

Evotec AG

Johnson & Johnson

Medestea Research & Production SpA

P2X Purinoceptor 7 (P2Z Receptor or P2RX7)-Drug Profiles

AFC-5128-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BIL-010t-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BIL-06v-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EVT-401-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JNJ-47965567-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JNJ-5446-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize P2X7 Receptor for Central Nervous System-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize P2RX7 for CNS Disorders, Autoimmune Disorders and Inflammation-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

WITH-1101-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

P2X Purinoceptor 7 (P2Z Receptor or P2RX7)-Dormant Products

P2X Purinoceptor 7 (P2Z Receptor or P2RX7)-Discontinued Products

P2X Purinoceptor 7 (P2Z Receptor or P2RX7)-Product Development Milestones

Featured News & Press Releases

Mar 03, 2017: Biosceptre publishes a clinical study of topical drug BIL010t as therapy for Basal cell carcinoma

Dec 18, 2014: Alzheimer's Drug Discovery Foundation And Axxam Continue Their Successful Collaboration To Develop Novel Therapeutics For Alzheimer's Disease

Jul 22, 2014: Biosceptre Announces Positive Phase I Results for BIL-010t to Treat Basal Cell Carcinoma

Jan 25, 2012: Affectis Receives European Patent For AFC-5128 And Other P2X7 Antagonists

Jun 29, 2009: Evotec Announces The Successful Completion Of The First Phase I Study With EVT 401

Oct 09, 2008: Evotec Announces Phase I Initiation With P2X7 Antagonist

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Figures

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Top 10 Indications, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017

List of Tables

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Indications, H2 2017

Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Pipeline by Affectis Pharmaceuticals AG, H2 2017

Pipeline by Axxam SpA, H2 2017

Pipeline by Biosceptre International Ltd, H2 2017

Pipeline by Evotec AG, H2 2017

Pipeline by Johnson & Johnson, H2 2017

Pipeline by Medestea Research & Production SpA, H2 2017

Dormant Projects, H2 2017

Discontinued Products, H2 2017

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Affectis Pharmaceuticals AG

Axxam SpA

Biosceptre International Ltd

Evotec AG

Johnson & Johnson

Medestea Research & Production SpA

P2X Purinoceptor 7 (P2Z Receptor or P2RX7) Therapeutic Products under Development, Key Players in P2X Purinoceptor 7 (P2Z Receptor or P2RX7) Therapeutics, P2X Purinoceptor 7 (P2Z Receptor or P2RX7) Pipeline Overview, P2X Purinoceptor 7 (P2Z Receptor or P2RX7) Pipeline, P2X Purinoceptor 7 (P2Z Receptor or P2RX7) Pipeline Assessment

select a license
Single User License
USD 3500 INR 245000
Site License
USD 7000 INR 490000
Corporate User License
USD 10500 INR 735000

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com